Horizon Lifts FY15 Sales Outlook - Quick Facts

(RTTNews) - Horizon Pharma Plc. (HZNP), a biopharmaceutical company, said it expects second quarter net sales to be in the range of $170 million to $172 million. Analysts currently expect second quarter revenue of $138.26 million.

For full year 2015, the company raised it net sales to a range of $660 million to $680 million from its previous range of $590 million to $610 million. Analysts now expect net sales of $611.60 million.

"Our expected second quarter sales results significantly exceed expectations, driven by rapidly accelerating prescription growth in our primary care and specialty business units and the continued addition of new patients to ACTIMMUNE and RAVICTI," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "This outperformance is a testament to Horizon's commercial execution and also demonstrates our ability to enhance the growth of medicines we add to our highly successful commercial model.